Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month

By Chris Lau, InvestorPlace Contributor

Axovant Sciences soared last week after AXON stock presented AXO-Lenti-PD, a gene therapy product that treats Parkinson's Disease.

As Spinal Stocks Climb Toward Yearly Highs, There’s Still Room for Upside

By Chris Lau, InvestorPlace Contributor

Companies in the medical appliances and equipment market of spines are sharply above yearly lows. Analyst coverage in the spinal stock sector is giving those stocks a temporary boost.

Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason

By Chris Lau, InvestorPlace Contributor

Celgene buying out Agios would make sense but either way the company's work on cellular metabolism and gene deleting is interesting the bulls the most. Agios stock is a good buy on its own merits.

Nektar Therapeutics Stock Is a Buy After a Major Market Misread

By Chris Lau, InvestorPlace Contributor

Sellers dominated the trading action on Nektar stock after its preliminary clinical results. Over-reaction or justified selling? The market simply did not understand the results, hurting the NKTR stock price.

After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall

By Chris Lau, InvestorPlace Contributor

Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.

Load More